-
Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
Wednesday, March 7, 2018 - 12:31pm | 631Read More...Pharmaceutical manufacturers are lobbying to reverse Medicare Part D discounts before Congress passes its omnibus spending bill by March 23. By Height Capital Markets’ assessment, the odds are marginally in big pharma's favor. The campaign-leading Pharmaceutical Research and...
-
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
Tuesday, May 16, 2017 - 11:15am | 371Read More...Shares of Pfizer Inc. (NYSE: PFE) were trading lower by nearly 2 percent Tuesday morning after analysts at Citi downgraded the stock and offered three alternative recommendations. Citi's Andrew Baum downgraded Pfizer's stock rating from Neutral to Sell with a price target slashed from $38 to $31....
-
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
Monday, October 5, 2015 - 3:06pm | 502Read More...After speaking with industry insiders and legal experts, Leerink believes that the selloff in pharmaceutical stocks is overdone. Experts see “near zero odds” that Hillary Clinton’s drug pricing plan will become law without significant changes. Leerink believes that the most...
-
Barclays Raises Walgreen Price Target Following Q1 Print
Wednesday, December 24, 2014 - 12:06pm | 248Read More...Meredith Adler of Barclays maintained an Equal-Weight rating on Walgreen Company (NYSE: WAG) with a price target raised to $72 from a previous $68 following the company's first quarter results. According to Adler, Walgreen's results were “ahead of expectations” and during the earnings call, the...
